Last reviewed · How we verify
Atorvastatin 40mg, QD
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.
At a glance
| Generic name | Atorvastatin 40mg, QD |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Atorvastatin competitively binds to HMG-CoA reductase and blocks the conversion of HMG-CoA to mevalonate, a critical early step in cholesterol biosynthesis. This leads to decreased hepatic cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary and secondary prevention of cardiovascular disease
- Reduction of risk of myocardial infarction and stroke
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes (ALT/AST)
- Headache
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
- Atorvastatin Therapy on Xanthoma in Alagille Syndrome (PHASE4)
- Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (PHASE2)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis (PHASE2)
- Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PHASE4)
- Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Measuring Oncological Value of Exercise and Statin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin 40mg, QD CI brief — competitive landscape report
- Atorvastatin 40mg, QD updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI